Affinity-based detection of ligand-encoded synthetic biomarkers
First Claim
1. A method comprisingadministering to a subject a synthetic particle comprising a carrier domain linked by an enzyme susceptible substrate to a detectable marker that comprises a capture ligand that is a hapten connected through a GluFib peptide to a detection ligand,wherein, when the synthetic particle encounters an enzyme within the subject resulting in in vivo cleavage of the enzyme susceptible substrate, the detectable marker is released from the carrier domain to renal clearance into urine;
- obtaining a sample from the subject; and
performing a capture assay on the sample to detect the detectable marker, wherein the presence of the detectable marker in the sample is indicative of the enzyme being present in an active form within the subject.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention relates to methods and products associated with in vivo enzyme profiling. In particular, biomarker nanoparticles capable of quantitatively detecting enzymatic activity in vivo are described. These nanoparticles can be used to detect in vivo enzyme activity. The invention also relates to products, kits, and databases for use in the methods of the invention.
-
Citations
22 Claims
-
1. A method comprising
administering to a subject a synthetic particle comprising a carrier domain linked by an enzyme susceptible substrate to a detectable marker that comprises a capture ligand that is a hapten connected through a GluFib peptide to a detection ligand, wherein, when the synthetic particle encounters an enzyme within the subject resulting in in vivo cleavage of the enzyme susceptible substrate, the detectable marker is released from the carrier domain to renal clearance into urine; -
obtaining a sample from the subject; and performing a capture assay on the sample to detect the detectable marker, wherein the presence of the detectable marker in the sample is indicative of the enzyme being present in an active form within the subject. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 20, 21)
-
-
17. A method comprising:
-
administering to a subject a particle comprising a carrier domain linked via an enzyme cleavable linker to a detectable marker that includes a hapten, a GluFib peptide, and a detection ligand, wherein a size of the particle inhibits renal clearance and wherein the particle is cleaved in vivo by an enzyme to release the detectable marker, which admits of renal clearance and is excreted in urine; obtaining a sample from the subject; and assaying the sample for the detectable marker via a capture assay in which an antibody on a substrate binds to the hapten and a detectable reporter binds to the detection ligand to provide a signal indicative of the enzyme being active within the subject. - View Dependent Claims (18, 19, 22)
-
Specification